974
Participants
Start Date
February 18, 2020
Primary Completion Date
April 25, 2022
Study Completion Date
April 25, 2022
Ad26.ZEBOV
Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
MVA-BN-Filo
Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
Placebo
Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
Alliance for Multispeciality Research, Norfolk
Coastal Clinical Research, Inc, Mobile
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville
Central Kentucky Research Associates, Inc., Lexington
The Center For Pharmaceutical Research, Kansas City
Clinical Research Consortium, an AMR company, Tempe
Clinical Research Consortium, an AMR company, Las Vegas
Janssen Vaccines & Prevention B.V.
INDUSTRY